CEO & Co-Founder of Gryphon Bio and Owl Therapeutics
BIOGRAPHY
June 25, 2025 Time: 8:00 AM PT, 11:00 AM ET
From Blind Spot to Biomarker: Transforming Brain Health Monitoring with ImmunoPCR
Speakers
-
Aleksandra Hemm
Product Manager, Thermo Fisher ScientificBIOGRAPHY
Event Date & Time
Date: June 25, 2025
Time: 8:00 AM PT, 11:00 AM ET
Abstract
Traumatic brain injury, together with adjacent brain conditions such as Alzheimer’s disease, is a global health crisis. In this presentation, Aleksandra Hemm, Product Manager from Thermo Fisher Scientific, introduces high-sensitivity immunoassay, including ImmunoPCR solutions for the detection of low-abundance protein biomarkers involved in neurological disorders, such as Neurofilament Light (NF-L), Tau, and TNFα. Dr. William Haskins, CEO & Co-Founder of Gryphon Bio and Owl Therapeutics™, describes a proteomic workflow for the discovery of brain biomarkers and progress in the development of proprietary ImmunoPCR reagents for blood tests for monitoring brain health. Gryphon’s advanced workflow has been successfully powered by Thermo Fisher Scientific’s high sensitivity ImmunoPCR solutions for:
- Proximity extension assay-based proteomic discovery of blood biomarkers with the Olink™ platform
- Proximity ligation assay-based clinical assay development with the Invitrogen™ ProQuantum™ platform
These complementary ImmunoPCR-based technologies, incorporating PCR amplification of oligonucleotide-labeled antibodies that bind protein biomarker targets, offer several benefits for brain biomarker measurements in various biofluids.
Gryphon’s focus is on transforming brain health with highly scalable and cost-effective technologies for longitudinal monitoring of novel biomarkers, from brain cells susceptible to aging, infection, injury, and disease. For 1), Gryphon has partnered with Owl Therapeutics to harness the Olink™ platform to discover distinct “waves” of elevated levels of novel brain biomarkers, as well as therapeutic targets, in biofluid samples from traumatic brain injury, mild cognitive impairment, and Alzheimer’s disease patients. For 2), Gryphon is now partnering with Thermo Fisher Scientific to develop clinical assays for a differentiated panel of brain biomarkers with the ProQuantum™ platform and to verify these findings in blood samples from large historical cohorts of patients.
Learning Objectives
- Gain insights into Gryphon’s process for transitioning from liquid chromatography-tandem mass spectrometry-based workflows to ImmunoPCR-based workflows for brain biomarkers
- Explore overlaps in brain biomarkers among adjacent brain conditions
- Discover how Thermo Fisher Scientific ’s Olink™ and Invitrogen™ ProQuantum™ platforms are accelerating Gryphon’s development of proprietary Immuno-PCR reagents for blood tests for monitoring brain health
Learn more about ELISA, ProQuantum and Multiplex Immunoassays for Neurobiology here >>
© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
You May Also Like
SEP 30, 2025 | 9:00 AM
Long-read sequencing is transforming the landscape of genomic research, offering exceptional resolution and accuracy in the analysis of complex genetic structures. From research in genetic a...
SEP 30, 2025 | 10:00 AM
Biosafety cabinets (BSCs) are a cornerstone of modern laboratory safety, yet many users lack a clear understanding of how they work, how to use them properly, and how to distinguish between...
OCT 01, 2025 | 1:00 PM
Laboratories are under growing pressure to meet both stringent safety standards and ambitious sustainability goals—often with limited resources. This webinar, hosted by Erlab, a global...
OCT 02, 2025 | 8:00 AM
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to iso...
OCT 07, 2025 | 7:00 AM
The analysis of protein behavior and protein interactions is central in drug research. In this web seminar, we will show you how the automation of protein purification and downstream thermal...
OCT 07, 2025 | 7:00 AM
This presentation explores the scientific rationale, preclinical validation, and early clinical translation of STAR-LLD—a novel, continuous low-dose percutaneous lenalidomide delivery...
Loading Comments...